Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins
Mipomersen, an antisense oligonucleotide that reduces hepatic production of apoB, has been shown in phase 2 studies to decrease plasma apoB, LDL cholesterol (LDL-C), and triglycerides. ApoC-III inhibits VLDL and LDL clearance, and it stimulates inflammatory responses in vascular cells. Concentration...
Main Authors: | Jeremy D. Furtado, Mark K. Wedel, Frank M. Sacks |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2012-04-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520405723 |
Similar Items
-
Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans
by: Jeffrey S. Cohn, et al.
Published: (2003-10-01) -
Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE
by: Jeffrey S. Cohn, et al.
Published: (2004-08-01) -
ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan
by: Katherine Olin-Lewis, et al.
Published: (2002-11-01) -
Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia
by: Frank G. Schaap, et al.
Published: (2006-10-01) -
ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression
by: Gery Gerritsen, et al.
Published: (2005-07-01)